library.onepin.app/methylene-blue Peptide Education Library
Education only, not medical advice 21+ Every dose is an example to finalize with a licensed provider
Cognitive & Mood Dietary supplement

Methylene Blue

Methylthioninium Chloride · MB · Tetramethylthionine

0.5-1mg/kg – 0.5-1 mg/kg (approx 10-50mg) Oral 1x daily

Methylene blue (methylthioninium chloride) is a synthetic phenothiazine dye first produced in 1876, making it one of the oldest synthetic drugs in medicine. It is FDA-approved for the treatment of acquired methemoglobinemia (where it acts as an electron carrier to reduce methemoglobin back to functional hemoglobin) and is on the WHO List of Essential Medicines. It has a long history of use in diagnostic procedures, as a surgical dye, and as an antiseptic.

Quick Start
Route
Oral
Start low
0.5-1mg/kg Oral
Frequency
1x daily
Timing
Can be taken with food to reduce GI discomfort

Oral or IV. Morning preferred (energizing). Low doses (0.5-2mg/kg). Can stain urine blue.

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first
Conservative start
0.5-1mg/kg · Oral · 1x daily
conservative starter
0.5-1mg/kg
1x daily
Intermediate
Mitochondrial Respiration
0.5-1 mg/kg (approx 10-50mg) · Oral · Daily
human study · Rojas, Bruchey & Gonzalez-Lima 2011 (Prog Neurobiol 96:32-45)
Will turn urine blue/green. Must use USP (pharmaceutical) grade; industrial/chemical grade contains heavy metals.
0.5-1 mg/kg (approx 10-50mg)
Daily
01

How it works

Acts as an alternative electron carrier in the mitochondrial electron transport chain, cycling between oxidized (blue) and reduced (colorless leuco-methylene blue) forms. It can accept electrons from NADH and donate them directly to cytochrome c, bypassing Complex I-III blockades. This sustains ATP production and reduces electron leak/ROS generation from dysfunctional mitochondria.

In methemoglobinemia, methylene blue is reduced by NADPH-methemoglobin reductase to leucomethylene blue, which then donates electrons to reduce methemoglobin (Fe3+) back to functional hemoglobin (Fe2+), restoring oxygen-carrying capacity.

Exhibits dose-dependent hormetic behavior: at low concentrations (0.5-2mg/kg), it acts as an antioxidant by improving electron flow and reducing ROS. At high concentrations, it overwhelms reduction capacity and generates superoxide, becoming pro-oxidant. This hormetic window is critical for therapeutic use.

02

What to expect

Early
Days 1–7

Days 1-7: Blue urine (normal and expected). Possible subtle cognitive effects. Mild GI adjustment period.

03

Evidence

HumanStrong
AnimalStrong
In-vitroPresent

Claims we could not support

No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.

Dose/route: 0.5-1mg/kg; Oral; 1x daily. No checked live PubMed abstract verified this exact displayed dose, route, and frequency for the same molecule/formulation and relevant population.

Mechanism: Acts as an alternative electron carrier in the mitochondrial electron transport chain, cycling between oxidized (blue) and reduced (colorless leuco-methylene blue) forms. It can accept electrons from NADH and donate them directly to cytochrome c, bypassing Complex I-III blockades. This sustains ATP production and reduces electron leak/ROS generation from dysfunctional mitochondria.. No checked live PubMed abstract provided an exact-molecule/formulation sentence supporting this source-JSON mechanism claim.

Primary safety claim: Blue-green discoloration of urine (universal, harmless, expected). No checked live PubMed abstract directly verified this source-JSON safety claim at the displayed formulation, route, and regimen.

04

Interactions & stacking

Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.

Documented together

RapamycinmTOR inhibition and mitochondrial electron transport support address aging through independent mechanisms
EpicatechinBoth support mitochondrial function - epicatechin via PGC-1alpha biogenesis, methylene blue via electron transport bypass
EpithalonNo direct interaction - telomerase activation and mitochondrial support are complementary
BPC-157No pharmacological interaction - BPC-157 tissue repair works via distinct pathways (NO, GH)

Keep separate

SSRIs and SNRIsMethylene blue is a potent MAO-A inhibitor - combining with serotonergic medications causes potentially fatal serotonin syndrome
Injectable Vitamin CVitamin C can reduce methylene blue to leucomethylene blue, disrupting its electron carrier cycling and therapeutic mechanism
MelatoninMethylene blue inhibits MAO-A which metabolizes serotonin and melatonin - may cause unpredictable melatonin accumulation
Dasatinib+QuercetinQuercetin has redox activity that may interfere with methylene blue's precise hormetic dose-response - unpredictable oxidative interactions

Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.

05

Pharmacokinetics

Illustrative plasma concentration · 24 h
Half-life
~5-6 hours

Terminal half-life ~24 hours due to tissue distribution

Peak · Tmax
~1-2 hours

Oral, immediate IV

Elimination
~4-5 days

Due to extensive tissue binding and long terminal half-life

Bioavailability
~72%

Oral. ~100% IV.

Duration of action
12-24 hours

Mitochondrial electron carrier effects persist due to tissue retention

Clearance

Hepatic (reduction to leucomethylene blue) and renal (excreted as parent compound and metabolites in urine)

Storage. Store at room temperature (15-25C). Protect from light. Aqueous solutions are stable but light-sensitive. Pharmaceutical grade (USP) required for medical use.

06

Regulatory status

FDA-approved (ProvayBlue, generic) for treatment of acquired methemoglobinemia. Investigational for Alzheimer's disease (LMTM failed Phase III primary endpoints). Off-label use for cognitive enhancement, vasoplegic syndrome, and ifosfamide encephalopathy. WHO Essential Medicine.

Put it to work

Calculate, log & track

Open Methylene Blue straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Methylene Blue in the app →

Go deeper

The guide & community

The complete Methylene Blue walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗
Open in app Community

Track it in OnePin. Log vials, draws, and protocols in the app.